AstraZeneca completes rights sale on Imdur; closes buy from Takeda Pharma
3rd May 2016 07:06
(ShareCast News) - AstraZeneca said it has completed the divestment of the global rights to angina treatment Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding Co. Under the agreement, AstraZeneca will receive $19 m for the r
Read moreAstraZeneca first-quarter revenue up, earnings down
29th Apr 2016 07:38
(ShareCast News) - AstraZeneca posted a drop in first-quarter earnings but a rise in revenue as core research and development costs increased, reflecting recent acquisitions. Core earnings per share fell 7% at constant currency and 12% in dollar terms to 95 cents, while revenue was up 5% at constant
Read moreFTSE 100 movers: Standard Chartered lifted while AstraZeneca sinks
26th Apr 2016 14:25
(ShareCast News) - The FTSE 100 was treading water on Tuesday afternoon, managing to keep itself in the black in contrast to its sibling index. Emerging markets-exposed bank Standard Chartered was among the top performers, as investors showed their approval of the bank's ongoing turnaround. It poste
Read moreAstraZeneca, Ironwood agree US licensing deal for gout treatment
26th Apr 2016 09:40
(ShareCast News) - AstraZeneca said it had entered a licensing agreement with Ironwood Pharmaceuticals over exclusive US rights to Zurampic, which is used to treat hyperuricemia associated with uncontrolled gout. Ironwood will get rights to Zurampic and exclusive US rights to the fixed-dose combinat
Read moreAstraZeneca's Bevespi Aerosphere approved by US FDA
26th Apr 2016 08:06
(ShareCast News) - AstraZeneca said announced that the US Food and Drug Administration has approved its Bevespi Aerosphere inhalation aerosol for treating patients with chronic obstructive pulmonary disease. Bevespi Aerosphere or glycopyrrolate and formoterol fumarate is used for the long-term, main
Read moreSunday newspaper round-up: AstraZeneca, Monarch Airlines, HSBC, Opec deal
17th Apr 2016 16:53
(ShareCast News) - AstraZeneca has held talks with US-based rival Medivation that could see it make a $10bn (£7bn) takeover bid, where it will battle France's Sanofi, which had a bid rejected last week, and others. Although oncology drug maker Medivation has been criticised for "price gouging" by Am
Read moreBroker tips: Aviva, Diageo, Astrazeneca
12th Apr 2016 12:42
(ShareCast News) - Recent underperformance led analysts at Credit Suisse to remove Aviva from their Europe Focus List, but they expected the stock's price to close the gap versus its peers over the next few years. The decision to remove the stock from that list was triggered by the shares' breach of
Read moreThursday broker round-up
7th Apr 2016 15:32
(ShareCast News) - Zoopla: UBS downgrades to neutral with a target price of 260p. Caledonia Mining: Panmure Gordon downgrades to hold, 61p target. Burberry: RBC downgrades underperform with a target price of 1300p, JP Morgan reiterates neutral with a target of 1400p and UBS keeps at buy with a targ
Read moreFTSE 100 movers: M&S climbs on update; Glencore slips on downgrade
7th Apr 2016 13:04
(ShareCast News) - London's FTSE 100 index was down 0.1% to 6,154.99 at 1410 BST, although retailer M&S bucked the trend. Payments processor Worldpay was under pressure after private equity groups Advent International and Bain Capital sold a 12.5% stake in the company. Glencore fell after JP Morgan
Read moreLondon-listed pharmas rally as Pfizer-Allergan deal collapses
6th Apr 2016 10:20
(ShareCast News) - Shares in pharmaceuticals companies Shire, AstraZeneca and GlaxoSmithKline rallied on Wednesday as investors bet that the termination of Pfizer's agreement to buy Allergan might make the London-listed companies bid targets. US drug maker Pfizer said on Wednesday that its $160bn ag
Read moreTuesday broker round-up
29th Mar 2016 16:51
(ShareCast News) - Synthomer: Berenberg downgrades to hold with a target price of 345p. Next: Goldman Sachs downgrades to neutral, 6400p target, Canaccord downgrades to hold with a target price of 6025p, Deutsche Bank reiterates buy with a target of 6850p and Credit Suisse stays at underperform, 560
Read moreSanofi poaches top AstraZeneca scientist
29th Mar 2016 11:27
(ShareCast News) - Sanofi revealed it had poached one of AstraZeneca's top scientists on Tuesday, appointing Yong-Jun Liu as its new research head. The French drugmaker said Liu's appointment would take effect on 1 April, and he would report to its president of global research and development Elias
Read moreLondon pre-open: Stocks seen touch higher after Easter break
29th Mar 2016 07:44
(ShareCast News) - London stocks are set to open a touch higher on Tuesday as traders get back to their desks following the long Easter weekend. The FTSE 100 is seen starting six points higher than Friday's close at 6,113. Later on in the day, investors will eye a speech from Federal Reserve Chair
Read moreApproval in Japan for AstraZeneca lung cancer treatment
29th Mar 2016 07:18
(ShareCast News) - The Japanese Ministry of Health, Labour and Welfare delivered good news to AstraZeneca on Tuesday morning, approving the FTSE 100 drug company's Tagrisso (osimertinib) tablets for the treatment of patients with epidermal growth factor receptor (EGFR) T790M mutation-positive inoper
Read moreLondon pre-open: Stocks seen lower as investors continue to digest Brussels attacks
23rd Mar 2016 07:37
(ShareCast News) - London stocks were set to open lower on Tuesday following a mostly negative session in Asia as investors continue to digest the terror attacks in Brussels. The FTSE 100 is seen starting 25 points lower than Tuesday's close at 6,167. "While travel and hotel stocks took a bit of a
Read more